HS-20093 + bevacizumab + 5-fluorouracil + leucovorin

This drug is a **combination regimen** consisting of **HS-20093**, **bevacizumab**, **5-fluorouracil**, and **leucovorin**. - **HS-20093** is a fully humanized IgG1 antibody-drug conjugate (ADC) targeting B7-H3, an immune checkpoint protein highly expressed on solid tumors. This ADC delivers a cytotoxic payload directly to B7-H3 expressing tumor cells, combining targeted therapy with direct cytotoxicity[1][3][5][7]. - **Bevacizumab** is a humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), blocking angiogenesis and thus restricting tumor blood supply[2][4][8]. - **5-fluorouracil** (5-FU) is a pyrimidine antimetabolite that inhibits thymidylate synthase, leading to impaired DNA synthesis and cytotoxicity, primarily in rapidly dividing cells (such as malignant cells). - **Leucovorin** (folinic acid) is not cytotoxic itself but enhances the binding of 5-FU to thymidylate synthase, increasing its antitumor activity and allowing for higher efficacy in chemotherapeutic regimens. The combination is being investigated in advanced solid tumors for synergistic antitumor effect, with **HS-20093** delivering precision-targeted cytotoxicity, **bevacizumab** blocking angiogenesis, and **5-FU + leucovorin** providing well-established cytotoxic and chemosensitizing effects.